| Name | Title | Contact Details |
|---|---|---|
Mark Nolan |
Director - Leadership Development | Profile |
Leslie Paiz |
Director of Talent Attraction and Development | Profile |
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.
BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.
Florida Hospital Orlando is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Elektrofi is a biotechnology company focused on improving administration for a wide range of medicines including monoclonal antibodies, therapeutic proteins, and other large molecule drugs. Its breakthrough formulation platform enables stabilized, highly concentrated formulations for subcutaneous administration. The company is using this technology to transform therapies that are administered intravenously, and to enhance injectable products by reducing the volume and frequency of dosing. Elektrofi partners with pharmaceutical companies to jointly develop patient-friendly delivery solutions. Headquartered in Boston, the company`s founding team of MIT engineers and scientists are shaping the future of biologics delivery.
Our vision is to become the leading innovative global life-sciences company that unlocks the potential of T-cell biology and combines it with the power of T-cell engineering excellence to provide cures for patients. Through our model of seamless and rapid integration of research, translational medicine, manufacturing science, clinical development and customer-centric approaches, we will design and deliver enhanced state-of-the-art solutions for patients in a host of disease areas using Chimeric Antigen Receptors (CARs), Gene edited T-Cells, T regulatory cells (Treg), and engineered T Cell Receptors (TCRs)